OXFORD, England, June 06, 2024--Exscientia plc (Nasdaq: EXAI) today announced the appointment of two technology and clinical development leaders to senior roles to significantly strengthen the impact of differentiating technology applications as well as focused oncology pipeline development.
The average of price targets set by Wall Street analysts indicates a potential upside of 57.2% in Exscientia (EXAI). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
OXFORD, England, May 30, 2024--Exscientia plc (Nasdaq: EXAI) today announced that members of Exscientia management will participate in the following upcoming investor conferences in June: